KARD Stock — Kardigan, Inc. Common Stock

Kardigan, Inc. Common Stock (KARD)

Updated October 16, 2026.

KARD is a Stock. Total return is -40.8% over the past 0.3 years, 43.3 points behind SPY at 2.5%.

Kardigan, Inc. is a biopharmaceutical company developing medicines for cardiovascular diseases, particularly cardiomyopathies and heart failure. The company uses a proprietary platform combining AI-based tools, real-world clinical data, and cardiac-specific analytics to guide drug development and clinical trials, supplemented by the FDA-cleared algorithms and patient data from its Prolaio cardiovascular platform. The company does not currently distribute to shareholders.

KARD performance versus SPY

Price and return data through 2026-10-16.

Total return is -40.8% over the past 0.3 years, 43.3 points behind SPY at 2.5%.

KARD key facts

Asset type

Stock

Asset class

Equity

Inception date

06/18/2026

Distribution frequency

None

Last close

$13.03 (as of 2026-10-16)

Market cap

$1,218,353,198

Average volume

717612.0

Payout ratio

0.0%

EPS

$-10.65

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

KARD risks and drawbacks

Total return has trailed SPY over the available window.

Who may consider KARD — and who may not

It is a weaker fit for investors who need monthly cash flow (KARD does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on KARD

• All tickers starting with K

Tagged: Healthcare.

Frequently asked questions